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Chemokine receptors are G-protein-coupled, seven-
transmembrane-spanning surface receptors that play
key roles in cell trafficking, cell motility, and survival.
These receptors are activated by small molecular
weight chemotactic cytokines called chemokines.
Chemokine receptors play roles in the migration and
localization of normal T cells (and other leukocytes)
during physiological responses in inflamed or in-
fected skin. In cancer cells, these receptors may also
facilitate tumorigenesis, metastasis, and resistance to
immune-mediated killing. This review will focus on
recent data that reveal potential roles of specific
chemokine receptors, including CCR4, CXCR4, and
CCR10, in the pathophysiology of cutaneous T-cell
lymphoma, including mycosis fungoides and Se´zary
syndrome.
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INTRODUCTION
The cutaneous T-cell lymphomas (CTCLs) represent a diverse
group of skin-localized lymphomas (Hwang et al., 2008).
Diverse in clinical presentation, most tend to be indolent and
limited in distribution, although some forms can be rapidly
progressive and eventuate in systemic involvement. The
CTCL entities known classically as mycosis fungoides (MF;
presenting with patches, plaques, tumors) and Se´zary
syndrome (SS; presenting with leukemic T cells in the blood
and erythroderma) comprise the large majority of CTCL cases
(Criscione and Weinstock, 2007). There has been substantial
progress in understanding the pathogenesis of MF and SS,
although the etiology of these two diseases is still unknown.
The immunological abnormalities present in CTCL have
been reviewed in detail by several groups (Kim et al., 2005;
Hwang et al., 2008)). In most cases of MF and SS, a clonal
expansion and activation of CD4-positive T cells results in the
release of cytokines and growth factors that stimulate the
proliferation of the epidermal keratinocytes (resulting in
thickening and/or scaling of the skin) and inflammation in
the epidermal and dermal compartments of skin (leading
to erythema) (Kim et al., 2005). How malignant T cells are
able to localize so specifically to skin remains one of the
most fascinating questions in the CTCL field. Recent data
from Campbell et al. (2007) and others focus on a family
of chemotactic receptors called ‘‘chemokine receptors’’ that
affect the homing of T cells to skin under inflammatory
conditions.
In the remainder of this overview, we will review the roles
of chemokine receptors in the biology of CTCL. Herein, we
will emphasize that chemokine receptors influence not only
migration, but also the survival of malignant cells in the skin
by activating prosurvival pathways that act independently of
migratory/adhesive pathways.
CHEMOKINES AND CHEMOKINE RECEPTORS IN CTCL
PATHOPHYSIOLOGY
The chemokines are a large group of chemotactic proteins
(B8–11 kDa in size) that are grouped into four families
(C, CC, CXC, and CX3C) based on the spacing of amino-
terminal cysteine residues (Charo and Ransohoff, 2006). The
chemokines (and their receptors) are generally known by
their systematic names, consisting of the family of the
chemokine followed by the letter ‘‘L’’, for ligand, or ‘‘R’’,
for receptor, and a number indicating their order of
discovery. The CC and CXC families form the majority of
known chemokines (currently B50). Chemokines interact
with cell surface, seven-transmembrane domain, G-protein-
coupled receptors. So far, more than 18 chemokine receptors
have been described. Some chemokine receptors bind to
multiple chemokines and vice versa, suggesting functional
redundancies within this protein family. Within the limited
scope of this review, we will discuss recent data regarding the
role of selected chemokine receptors in CTCL pathophysiol-
ogy. These receptors (CCR4, CCR10, CCR7, and CXCR4)
have been implicated by more than human expression data to
have potential novel roles in CTCL. Other potentially relevant
chemokine receptors are listed in Table 1.
Chemokines are noteworthy for their ability to stimulate
directional migration of nearly all classes of leukocytes.
T cells from different functional subsets (for example, Th1,
Th2, Th17, Treg, naı¨ve vs memory, and so on) express a
regulated set of chemokine receptors that allow them to
differentially respond to specific chemokines. Epidermal
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keratinocytes are capable of expressing multiple chemokines
(see Figure 1) that can attract a wide rage of leukocytes,
including T cells, to the epidermis (Scho¨n and Ruzicka,
2001). In addition to stimulating migration toward the
epidermis, chemokines increase the affinity and avidity of
b1 and b2 integrins on leukocytes for their endothelial
counter-receptors such as intercellular adhesion molecule-1.
In vivo, chemokine-dependent integrin activation leads to
firm adherence of leukocytes on the luminal surfaces of
vascular endothelial cells, which produce chemokines
themselves or acquire them from other cells in the
inflammatory milieu for ‘‘presentation’’ on endothelial cell-
surface proteoglycans (Figure 1).
Chemokines produced by other cells, namely epidermal
and dermal dendritic cells (DC) bearing yet-unidentified
skin antigens, may also play important roles in attracting
malignant T cells to form conjugates with these antigen-
presenting cells, leading to subsequent T-cell activation
(Figure 1). Experimental data indicate that DC synthesize
CCR4 ligands, which rapidly stimulate chemotaxis of, or
conjugate formation with, normal T cells (Tang and Cyster,
1999; Wu et al., 2001). DC-malignant T-cell conjugates
known as ‘‘Pautrier’s microabscesses’’ are specific histo-
pathological markers for MF and may be initiated by DC-
derived chemokines. The involvement of DC in CTCL
pathophysiology has been extensively reviewed by others
(Edelson, 2001).
The chemokine receptors CCR4 and CCR10 have both
been reported to participate in trafficking of T cells to the skin
under inflammatory conditions (Reiss et al., 2001; Homey,
2005). Both are selectively expressed by so-called
‘‘skin-homing’’ memory T cells (a subset of the total memory
T cells) that bear surface carbohydrate ligands to E-selectin,
an adhesion protein that is characteristically expressed by
Table 1. Chemokine receptors and selected chemokine ligands with potential involvement in CTCL
Chemokine receptor (expression
pattern) Ligand(s) (expression pattern) Evidence for roles in CTCL pathophysiology
CCR3 (a promiscuous receptor)
(T cells, eosinophils, other leukocytes)
CCL5, 7, 8, 11 and others (macrophages
and other cells)
CCR3 is expressed in CD30+ skin lymphoma (Kleinhans et al.,
2003)
CCR4 (T cells) CCL17, CCL22 (keratinocytes, DC,
endothelial cells)
CCR4 is involved in T-cell trafficking to skin (Campbell et al.,
2007). Its expression is increased in CLA+ T cells in CTCL patients
(Ferenczi et al., 2002) and is enhanced along with CCR10 and
CCR7 in SS patients (Sokolowska-Wojdylo et al., 2005). CCR4
expression is also observed in large cell transformation of MF
tumors (Jones et al., 2000)
CCR10 (skin-homing T cells,
melanocytes)
CCL27 (endothelial cells and
keratinocytes)
CCR10 is critical to T-cell trafficking to skin under inflammatory
conditions (Homey et al., 2002) and is expressed by malignant cells
in MF and SS (Notohamiprodjo et al., 2005)
CXCR3 (memory T cells and NK cells) CXCL9,10,11 (keratinocytes, endothelial
cells, fibroblasts, monocytes)
CXCR3 is expressed in low-grade MF (Lu et al., 2001)
CCR7 (DC, T cells) CCL21 (lymphatic endothelial cells,
LN endothelial cells)
CCR7 and CCL21 are instrumental in physiologic homing of T cells
to LN (Fo¨rster et al., 1999; Gunn et al., 1999); CCR7 shows high
expression by malignant MF and SS cells; it may facilitate nodal
metastasis (Kallinich et al., 2003); increased expression of CCR7 is
associated with LN infiltration in adult T-cell leukemia–Lymphoma
(Hasegawa et al., 2000).
CXCR4 (endothelial cells, leukcytes,
and many other cell types)
CXCL12 (stromal cells, including
fibroblasts as well as other cells)
Skin homing may involve CXCR4 signaling and downregulation of
CD26, a protease that cleaves CXCL12 (Narducci et al., 2006)
The cells that express the indicated receptor or ligand are indicated in brackets.
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CXCR3,4
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2) Activation
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Figure 1. Roles for chemokines in CTCL pathyphysiology and therapy.
Malignant T cells in CTCL have been shown to express a relatively small
number of chemokine receptors. Endothelial cells (EC), keratinocytes (KC),
and dendritic cells (DC) all produce a variety of chemokines that can regulate
the homing (1) of malignant (and normal) T cells via changes in EC adhesion,
stimulated chemotaxis toward epidermis, or movement toward activating DC,
respectively. DCs produce chemokines that mediate their adhesion to T cells
(for example, Pautrier’s microabscesses), thus stimulating activation (2) of
these T cells. KC- and DC-derived chemokines have the potential to activate
prosurvival pathways that diminish the capacity of T cells to undergo
apoptosis (3). Therapeutically, chemokine-tagged T cell antigens (4) that
are processed by skin DC have the potential to act as vaccines to enhance
a host antitumor immunity toward malignant T cells. Chemokine-tagged
toxins (5) have the potential to directly induce cell death in malignant
T cells bearing appropriate receptors (for example, CCR4).
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inflamed dermal blood vessels. Neutralizing antibodies to
CCL27 (the CCR10 ligand) dramatically reduces contact
dermatitis in murine models (Homey et al., 2002).
The role of CCR4, however, was somewhat less clear
because optimal inhibition of cutaneous inflammation in
CCR4-deficient mice was obtained only when CCL27
antagonists were given (Reiss et al., 2001). Recent data
indicate that CCR4 plays a critical role in antigen-dependent
T-cell-mediated inflammation in the skin, as only CCR4 wild-
type T cells specific for ovalbumin peptide were able to accu-
mulate efficiently in skin in response to ovalbumin peptide
(Campbell et al., 2007). Importantly, Campbell et al. (2007)
showed that adoptive transfer of CCR4-deficient OVA-
specific T cells in antigen-treated mice resulted in the same
increase in the peripheral pool of OVA-specific, E-selectin
ligandþ T cells as did CCR4 wild-type antigen-specific
T cells. Thus, the failure to accumulate OVA-specific CCR4-
negative T cells in the skin was likely to be attributable to
a trafficking defect to the skin. This data was supported by
their observation that CCR4-negative T cells home normally
to the gut, thus ruling out an intrinsic homing defect in these
cells (Campbell et al., 2007). While one must be cautious
about applying the results of murine studies to human
physiology, a fair number of clinical observational studies
suggest that CCR4 is generally very highly expressed among
CTCL cells in MF and SS patients (Table 1).
There is increasing evidence that cancer cells can use
chemokine receptors to alter their metastatic spread. Mecha-
nistically, chemokine receptors can alter the ability of cancer
cells to arrest on vascular endothelial cells (Cardones et al.,
2003). Moreover, chemokine receptor engagement results in
the activation of well-characterized prosurvival pathways
such as phosphatidylinositol-3-kinase and Akt (Kakinuma and
Hwang, 2006). The prosurvival function of chemokine
receptors in cancer cells is supported by data showing
that melanoma cells use CXCR4 and CCR10 to enhance cell
survival in the absence of serum or in the face of immune
attack (Kakinuma and Hwang, 2006). With CCR10, activa-
tion of phosphatidylinositol-3-kinase was required for
chemokine receptor activation to inhibit Fas- and T-cell-
dependent killing of melanoma cells in vitro. In T cells,
chemokine receptor activation suppressed cyclohexamide-
and serum deprivation-induced apoptosis (Youn et al., 2002;
Diaz-Guerra et al., 2007). With very high concentrations of
chemokine in vitro, however, chemokine receptor activation
in T cells may actually block proliferation (Ziegler et al.,
2007). Thus, the prosurvival functions of chemokine recep-
tors, in addition to their migratory functions, may also play
a role in the ability of local chemokines to determine the
composition of inflammatory cells at a particular site of
inflammation or infection (Figure 1).
While onlyB25% of circulating CD3þ and CD4þ T cells
express CCR4 (Narducci et al., 2006), CCR4 has been shown to
be much more frequently expressed on MF as well as SS cells
(see Figure 3a) (Ferenczi et al., 2002; Narducci et al., 2006).
CCL17, a CCR4 ligand, is produced by activated keratinocytes,
endothelial cells, and DC and is upregulated in the epidermis
and serum of patients with MF (Kakinuma et al., 2003). Similar
to CCL17, CCL27 (a CCR10 ligand) is increased in the serum of
MF/SS patients and can be a marker of disease activity (Kagami
et al., 2006). The CCL27 receptor, CCR10, is only infrequently
expressed on peripheral blood T cells, but it is enriched in
CLAþ skin-homing T cells and in CTCL cells (Homey et al.,
2002; Notohamiprodjo et al., 2005). CCL27, however, is
constitutively present in epidermal keratinocytes (basal layer)
under basal, noninflammatory conditions (Figure 2) and may
play a role in T-cell epidermotropism in MF. Recent evidence
from our laboratory suggests that CCL27 can be rapidly
released from activated keratinocytes, thus regulating cuta-
neous as well as nodal homing of T cells following transfer of
CCL27 to regional lymph nodes (LNs) via the afferent
lymphatics (Huang et al., 2008). CCR7, a receptor that appears
to be critical for migration of maturing skin DCs and selected T-
cell subsets to the LNs (Forster et al., 1999), is also expressed at
fairly high levels in Se´zary cells (Sokolowska-Wojdylo et al.,
2005) and may play a role in the tropism of these cells to
peripheral LNs, which constitutively synthesize CCR7 ligands
(that is, CCL19 and 21).
The CXCR4 chemokine receptor may also play a role in
homing of MF and SS cells. Loss of cell-surface antigens,
including CD7 and CD26, has been recognized as charac-
teristic of MF and SS (Scala et al., 1999). The downregulation
of CD26, a dipeptidylpeptidase, is particularly interesting
because CD26 cleaves and inactivates CXCL12, a CXCR4
ligand produced by stromal cells and fibroblasts in the
dermis. Inactivation of CD26 enhanced CXCL12-driven
chemotaxis of cell lines derived from SS patients (Narducci
et al., 2006), whereas soluble CD26 inhibited CXCR4-
mediated migration. Thus, the loss of CD26 on the Se´zary
cells may increase their ability to migrate to and/or survive in
the skin.
CHEMOKINE RECEPTORS AS THERAPEUTIC TARGETS
IN CTCL
Targeting CCR4 and CCR10, the two chemokine receptors
that appear to be frequently expressed by CTCL cells, may be
a novel therapeutic strategy for treating CTCL. It is currently
unknown whether targeting these two receptors, which are
Anti-CCL27 mlgG
10 µm
a b
Figure 2. CCL27 expression in normal human skin. Frozen sections of
normal human skin stained (a) with fluorescent (green) monoclonal antibody
specific for human CCL27 or (b) with a control isotype mouse IgG. Sections
were counterstained with 40,6-diamidino-2-phenylindole to visualize nuclei.
The dashed white lines indicate the approximate location of the epidermal
basement membrane. Bar¼ 10 mm, which is indicated in the image
on the left.
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expressed by normal skin-homing T cells, would result in
significant immunosuppression. A relatively small fraction of
the total T-cell population expresses these receptors. Thus,
eradication of CCR4 and CCR10-positive T-cell populations
would not render patients severely lymphopenic.
Small-molecule antagonists of CCR4 and CCR10 have yet
to be developed, but antibodies of CCR4 that induce
antibody-dependent cellular cytotoxicity have already
been reported (Ishida et al., 2004; Yano et al., 2007).
Furthermore, Richardson et al. reported that bexarotene
downregulates CCR4 expression and/or function, suggesting
another mechanism by which bexarotene is effective in CTCL
(Richardson et al., 2007). Novel chemokine-toxin fusion
proteins analogous to the IL-2-diphtheria toxin fusion protein
(denileukin diftitox) may be highly specific for skin-homing
T-cell populations if they used chemokines such as CCL17 or
CCL27 to direct binding to cutaneous T cells (Figure 1).
Ligation of the chemokine receptor with a fusion toxin would
result in endocytosis of the chemokine-toxin and cell death.
CCL17 molecules fused to the Pseudomonas exotoxin 38
(PE38) have already been shown to effectively kill lymphoma
cells that express CCR4 (Baatar et al., 2007) and thus they
may prove useful as therapeutic agents in MF and/or SS. The
in vitro inhibition of growth of a cell line derived from an SS
patient by CCL17-PE38 is shown in Figure 3b.
CONCLUSIONS
Chemokine receptors are likely to be involved in the skin-
tropism that characterizes CTCL. In addition to facilitating
firm arrest of skin-homing T cells on dermal vascular endo-
thelial cells, they provide directional cues for the migration
of T cells to specific compartments of the skin, including
the epidermis. Even after localizing in skin, chemo-
kine receptors may increase the survival of T cell, both
malignant and benign, through activation of well-recognized
survival pathways that inhibit apoptosis. The under-
standing of how chemokine receptors regulate trafficking
and survival provides motivation for the use of receptor
antagonists or antireceptor antibodies as novel therapeutic
agents.
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